Daniel Barber
Analyst
R&D
Board Member
Aquestive Therapeutics, Inc. (AQST)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Daniel Barber
Daniel Barber is recorded as Analyst at R&D and CEO and Board Member at Aquestive Therapeutics, Inc. (AQST). Aquestive Therapeutics, Inc. reported in an 8-K filed July 19, 2022 that Daniel Barber was appointed President and Chief Executive Officer, effective May 17, 2022. The proxy statement of Aquestive Therapeutics, Inc. reports total compensation of $3,493,559 for Daniel Barber in fiscal 2025, including a base salary of $659,885. Disclosed compensation is on record for 7 fiscal years. Daniel Barber has spoken on 1 earnings call across 1 company, most recently for Aquestive Therapeutics, Inc. on May 7, 2024.
“Mr. Barber was appointed as the Company's President and Chief Executive Officer on May 17, 2022, following his many years of service as the Chief Operating Officer and executive officer of the Company.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
R&D
Analyst
Source not stated
Current -
Current
Start not stated–present
-
Current
Start not stated–present
-
Aquestive Therapeutics, Inc. (AQST)
Source not stated
Current -
Start not stated–2022-04-29
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Aquestive Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Gregory B. Brown Chairman
- John S. Cochran Chairman
- A. Ernest Toth CFO
- A. Ernest Toth, Jr. CFO
- Cassie Jung COO
- Thomas A. Zalewski General Counsel
- Abigail L. Jenkins Board Member
- Julie Krop Board Member
- Marco Taglietti Board Member
- Richard J. Daly Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Aquestive Therapeutics, Inc. (AQST) | President and Chief Executive Officer | $659,885 | $3,493,559 |
| 2024 | Aquestive Therapeutics, Inc. (AQST) | Chief Executive Officer | $633,376 | $4,181,472 |
| 2023 | Aquestive Therapeutics, Inc. (AQST) | Chief Executive Officer | $600,000 | $2,416,088 |
| 2022 | Aquestive Therapeutics, Inc. (AQST) | Chief Executive Officer | $541,591 | $1,326,598 |
| 2021 | Aquestive Therapeutics, Inc. (AQST) | Chief Executive Officer Lori J. Braender\ Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | $424,058 | $1,157,103 |
| 2020 | Aquestive Therapeutics, Inc. (AQST) | Chief Operating Officer | $410,000 | $840,083 |
| 2019 | Aquestive Therapeutics, Inc. (AQST) | Chief Operating Officer | $388,846 | $1,195,228 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.